ASXL1 mutations are associated with distinct epigenomic alterations that lead to sensitivity to venetoclax and azacytidine.
Publication/Presentation Date
9-21-2021
Abstract
The BCL2-inhibitor, Venetoclax (VEN), has shown significant anti-leukemic efficacy in combination with the DNMT-inhibitor, Azacytidine (AZA). To explore the mechanisms underlying the selective sensitivity of mutant leukemia cells to VEN and AZA, we used cell-based isogenic models containing a common leukemia-associated mutation in the epigenetic regulator ASXL1. KBM5 cells with CRISPR/Cas9-mediated correction of the ASXL1
Volume
11
Issue
9
First Page
157
Last Page
157
ISSN
2044-5385
Published In/Presented At
Rahmani, N. E., Ramachandra, N., Sahu, S., Gitego, N., Lopez, A., Pradhan, K., Bhagat, T. D., Gordon-Mitchell, S., Pena, B. R., Kazemi, M., Rao, K., Giricz, O., Maqbool, S. B., Olea, R., Zhao, Y., Zhang, J., Dolatshad, H., Tittrea, V., Tatwavedi, D., Singh, S., … Verma, A. (2021). ASXL1 mutations are associated with distinct epigenomic alterations that lead to sensitivity to venetoclax and azacytidine. Blood cancer journal, 11(9), 157. https://doi.org/10.1038/s41408-021-00541-0
Disciplines
Medicine and Health Sciences
PubMedID
34548471
Department(s)
Department of Medicine
Document Type
Article